Morphine extended-release/naltrexone

Drug Profile

Morphine extended-release/naltrexone

Alternative Names: ALO-01; Embeda; KADIAN NT; Morphine ER/naltrexone; Naltrexone/morphine ER

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alpharma
  • Developer Pfizer
  • Class Morphinans; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Pain

Most Recent Events

  • 17 Oct 2014 The US FDA approves sNDA for Pain
  • 29 Jul 2014 The US FDA extends PDUFA date to October 2014 for sNDA review for Pain (PO)
  • 29 Jul 2014 The US FDA sets PDUFA date of July 2014 for sNDA review for Pain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top